Sinovac Life Sciences Co., Ltd.

This study tested a new vaccine (PCV24) designed to protect children aged 2-17 against pneumococcal disease, which can cause pneumonia and meningitis. The trial involved 119 healthy children and checked for side effects and immune response. The vaccine aims to cover 24 strains of…

This early-stage study tested a new oral rotavirus vaccine in 100 healthy people, from infants to adults. The main goal was to see if the vaccine is safe and well-tolerated, especially in infants. Researchers also checked if the vaccine triggered an immune response. The trial is …

This early-stage trial tested a new 13-valent pneumococcal conjugate vaccine in 310 healthy people, from infants 6 weeks old to adults 49 years. The goal was to check the vaccine's safety and how well it triggers the immune system to fight pneumococcal bacteria, which can cause p…

This study tested a new vaccine (PCV24) designed to protect against 24 types of pneumococcal bacteria, which can cause pneumonia and other infections. 385 healthy adults aged 18 and older received the vaccine to check its safety and how well it triggers the immune system. The tri…